Clinical Trial Update: GW273225 Therapy Added To Current Seizure Treatments In Patients With Partial Seizures [Phase 2]

View source ↗

Summary

A Phase 2 trial evaluating GW273225 as add-on therapy for partial seizures in epilepsy was withdrawn.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Epilepsy
• Partial Seizures

Drugs mentioned

• GW273225

Snippet

Sponsor: GlaxoSmithKline | Conditions: Epilepsy | Phase 2 | Status: WITHDRAWN